These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21301327)

  • 21. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Barkhof magnetic resonance imaging criteria predict early relapse in pediatric multiple sclerosis.
    Neuteboom RF; Ketelslegers IA; Boon M; Catsman-Berrevoets CE; Hintzen RQ;
    Pediatr Neurol; 2010 Jan; 42(1):53-5. PubMed ID: 20004863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years.
    Haas J; Maas-Enriquez M; Hartung HP
    Mult Scler; 2005 Oct; 11(5):562-7. PubMed ID: 16193894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapse management in multiple sclerosis.
    Thrower BW
    Neurologist; 2009 Jan; 15(1):1-5. PubMed ID: 19131851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.
    Haas J; Hommes OR
    Mult Scler; 2007 Aug; 13(7):900-8. PubMed ID: 17881400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.
    Danieli MG; Cappelli M; Malcangi G; Logullo F; Salvi A; Danieli G
    Ann Rheum Dis; 2004 Dec; 63(12):1649-54. PubMed ID: 15547090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative analysis of therapeutic options used for myasthenia gravis.
    Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
    Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging.
    Rovaris M; Filippi M
    Neurol Sci; 2005 Dec; 26 Suppl 4():S204-8. PubMed ID: 16388359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
    Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action.
    Achiron A; Barak Y; Goren M; Gabbay U; Miron S; Rotstein Z; Noy S; Sarova-Pinhas I
    Clin Exp Immunol; 1996 May; 104 Suppl 1():67-70. PubMed ID: 8625547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP; Bonzano L; Roccatagliata L; Cutter GR; Mancardi GL; Bruzzi P
    Ann Neurol; 2009 Mar; 65(3):268-75. PubMed ID: 19334061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
    Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
    Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of neuropsychological testing for guiding treatment decisions in paediatric multiple sclerosis.
    Penner IK; Hubacher M; Rasenack M; Sprenger T; Weber P; Naegelin Y
    Mult Scler; 2013 Mar; 19(3):366-8. PubMed ID: 22740487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
    Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
    Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.